<DOC>
	<DOCNO>NCT02427776</DOCNO>
	<brief_summary>The purpose study assess safety preliminary efficacy single infusion stimulate autologous CD4+ T cell patient Relapsing-Remitting Multiple Sclerosis . The study duration patient ( start baseline end follow-up ) 270 day .</brief_summary>
	<brief_title>A Trial Evaluating Both Safety Preliminary Efficacy Single Infusion Stimulated Autologous CD4+T Cells Patients With Relapsing- Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Males females 18 60 year age Patients closely follow least one year prior inclusion ( i.e . prior start baseline phase ) diagnosis disease make one year ago , ensure possible episode clinical relapse occur interval time record documented Multiple sclerosis meet 2010 revise McDonald criterion Relapsing/remitting type multiple sclerosis ( include clinically isolate syndrome image show brain lesion disseminate space time ) Radiologically active disease define least one gadoliniumenhancing lesion T1weighted magnetic resonance image brain scan perform recently ( i.e . within 3 month prior inclusion ) Diseasemodifying drug naïve patient patient stable adequately take diseasemodifying therapy ( interferon β1 , glatiramer acetate , dimethyl fumarate ) least six month inclusion ( NOTE : Other disease modify drug might add later date , depend result current investigation ) EDSS Score &lt; = 5.5 Positive predictive test vitro patient 's CD4+ cell reactivity immunogenic peptide Women childbearing age must negative pregnancy test must use adequate contraception treatment followup phase study ( three pregnancy test require prior study : ( 1 ) screening phase , ( 2 ) one week prior leukapheresis , ( 3 ) one week prior reinfusion autologous cell ) Fully inform write consent obtain Positive HLA DRB1*0101 , DRB1*0102 , DRB1*0401 , DRB1*0426 alleles combination previous allele . Evidence clinical relapse use intravenous oral corticosteroid within 30 day prior inclusion Therapeutic escalation anticipate ( include change disease modify drug ) , cellbased immunotherapy study , within next six month Significant coexist systemic disease include renal insufficiency Positive serology hepatitis B C , AIDS syphilis Participation another interventional clinical study , currently past three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>